Home

Our Approach

Our proprietary, highly targeted antibody drug conjugates (ADCs) are armed with highly potent pyrrolobenzodiazepine (PBD)-based warheads to selectively kill cancer cells.

Learn More ButtonLearn More Button

Pipeline

The selective targeting and unique mechanism of action of our ADCs enables the potential for our robust pipeline of therapies to have enhanced, durable efficacy and limited side effects in patients.

View Pipeline ButtonPipeline View Button

Clinical Trials

We are advancing our ADCs through clinical trials in multiple hematological and solid tumor indications, including a pivotal Phase II trial of ADCT-402 (loncastuximab tesirine) in patients with relapsed or refractory diffuse large B-cell lymphoma.

Find Out More ButtonFind Out More Button

News

ADC Therapeutics Presents Clinical Data on ADCT-402 and ADCT-301 in Subtypes of Relapsed or Refractory Lymphoma at the 15th International Conference on Malignant Lymphoma

ADC Therapeutics Presents Clinical Data on ADCT-402 and ADCT-301 in Subtypes of Relapsed or Refractory Lymphoma at the 15th International Conference on Malignant Lymphoma
Ongoing pivotal Phase II clinical trial of ADCT-402 in patients with relapsed or refractory diffuse large B-cell lymphoma anticipated to complete enrollment in third quarter of 2019 Pivotal Phase II clinical trial of ADCT-301 in relapsed or refractory Hodgkin lymphoma expected to commence in coming months Lausanne, Switzerland, June 21, 2019 – ADC Therapeutics, an

ADC Therapeutics Announces Completion of a Series E Financing Expansion

ADC Therapeutics Announces Completion of a Series E Financing Expansion
Brings total raised in the Series E round to $276 million Lausanne, Switzerland, June 12, 2019 – ADC Therapeutics, an oncology drug discovery and development company that specializes in the development of antibody drug conjugates (ADCs), today announced that it has closed a $76 million expansion of its Series E financing, bringing the total gross

ADC Therapeutics Announces Presentations at the 15th International Conference on Malignant Lymphoma

ADC Therapeutics Announces Presentations at the 15th International Conference on Malignant Lymphoma
Three oral presentations and one poster presentation Pyrrolobenzodiazepine-based antibody drug conjugates demonstrate potential for the treatment of relapsed or refractory lymphomas as single agents and in combination therapies Lausanne, Switzerland, June 12, 2019 – ADC Therapeutics, an oncology drug discovery and development company that specializes in the development of antibody drug conjugates (ADCs), today announced